Dai ichi Life Insurance Company Ltd Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

Dai ichi Life Insurance Company Ltd trimmed its stake in Johnson & Johnson (NYSE:JNJFree Report) by 12.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 292,073 shares of the company’s stock after selling 42,949 shares during the quarter. Johnson & Johnson makes up 1.0% of Dai ichi Life Insurance Company Ltd’s holdings, making the stock its 14th biggest position. Dai ichi Life Insurance Company Ltd’s holdings in Johnson & Johnson were worth $45,490,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. Independent Advisor Alliance increased its position in Johnson & Johnson by 0.9% in the second quarter. Independent Advisor Alliance now owns 153,337 shares of the company’s stock worth $25,380,000 after buying an additional 1,327 shares during the last quarter. Cypress Wealth Services LLC grew its stake in shares of Johnson & Johnson by 5.4% during the 2nd quarter. Cypress Wealth Services LLC now owns 9,725 shares of the company’s stock worth $1,547,000 after acquiring an additional 497 shares during the period. King Luther Capital Management Corp increased its holdings in Johnson & Johnson by 0.3% in the 2nd quarter. King Luther Capital Management Corp now owns 643,435 shares of the company’s stock worth $106,501,000 after acquiring an additional 2,027 shares during the last quarter. DORCHESTER WEALTH MANAGEMENT Co raised its stake in Johnson & Johnson by 0.6% in the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock valued at $11,758,000 after acquiring an additional 414 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Johnson & Johnson by 5.1% during the second quarter. Dimensional Fund Advisors LP now owns 8,843,038 shares of the company’s stock valued at $1,463,594,000 after purchasing an additional 430,445 shares during the last quarter. 68.40% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $158.76 on Wednesday. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. The stock has a market cap of $382.18 billion, a P/E ratio of 11.50, a PEG ratio of 2.68 and a beta of 0.53. The business’s 50-day moving average price is $157.47 and its two-hundred day moving average price is $159.25.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.28 by $0.01. The business had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. Johnson & Johnson’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.35 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10.67 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.00%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 34.47%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $167.00 to $180.00 in a research note on Friday, December 1st. Raymond James lifted their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Tuesday, January 23rd. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, November 17th. Finally, StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Monday. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $167.87.

Read Our Latest Report on JNJ

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.